NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NGNE NEUROGENE INC

Market Closed 11-22 16:00:00 EST

20.30

+4.71

+30.21%

盘后20.70

+0.40+1.97%

19:29 EST

High20.93	Low15.48	Vol1.06M
Open15.48	D1 Closing15.59	Amplitude34.96%
Mkt Cap301.55M	Tradable Cap134.49M	Total Shares14.85M
T/O20.13M	T/O Rate16.04%	Tradable Shares6.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":20.3,"timestamp":1732309200000,"preClose":15.59,"halted":0,"volume":1062923,"hourTrading":{"tag":"盘后","latestPrice":20.7,"preClose":20.3,"latestTime":"19:29 EST","volume":5873,"amount":119601.3413,"timestamp":1732321767359},"delay":0,"floatShares":6625300,"shares":14854700,"eps":-0.255445,"marketStatus":"Market Closed","change":4.71,"latestTime":"11-22 16:00:00 EST","open":15.48,"high":20.93,"low":15.48,"amount":20131036.706514,"amplitude":0.349583,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.255445,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":7,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":15.59,"preHourTrading":{"tag":"盘前","latestPrice":15.4683,"preClose":15.59,"latestTime":"09:26 EST","volume":1781,"amount":26973.378575,"timestamp":1732285585697},"postHourTrading":{"tag":"盘后","latestPrice":20.7,"preClose":20.3,"latestTime":"19:29 EST","volume":5873,"amount":119601.3413,"timestamp":1732321767359},"volumeRatio":1.0874014951775561,"impliedVol":0.9865,"impliedVolPercentile":0.6667},"requestUrl":"/m/hq/s/NGNE/wiki","defaultTab":"wiki","newsList":[{"id":"2485423690","title":"BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome Dies","url":"https://stock-news.laohu8.com/highlight/detail?id=2485423690","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485423690?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:15","pubTimestamp":1732223714,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Inc - Participant In Neurogene's Phase 1/2 Trial For Rett Syndrome DiesNov 21  - Neurogene Inc NGNE.O:NEUROGENE INC - PARTICIPANT IN NEUROGENE'S PHASE 1/2 TRIAL FOR RETT SYNDROME DIESNEUROGENE INC - FDA ALLOWS NEUROGENE TO PROCEED WITH PHASE 1/2 TRIAL USING 1E15 VG DOSESource text: [t.ly/aIzVh]Further company coverage: NGNE.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS13T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2485642335","title":"Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2485642335","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485642335?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:12","pubTimestamp":1732223549,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nL1N3MS14O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2485466428","title":"Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies","url":"https://stock-news.laohu8.com/highlight/detail?id=2485466428","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485466428?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:05","pubTimestamp":1732223100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MS13T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484287156","title":"Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=2484287156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484287156?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:00","pubTimestamp":1732082405,"startTime":"0","endTime":"0","summary":"Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category. Neurogene Inc. faces a significant business risk wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogene-inc-faces-uncertainty-with-ngn-101-program-amid-fda-challenges-and-strategic-hurdles?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogene-inc-faces-uncertainty-with-ngn-101-program-amid-fda-challenges-and-strategic-hurdles?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484910538","title":"Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2484910538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484910538?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:52","pubTimestamp":1732017120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2024 06:52 ET (11:52 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2484967993","title":"Neoleukin Therapeutics GAAP EPS of -$1.19 in-line","url":"https://stock-news.laohu8.com/highlight/detail?id=2484967993","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484967993?lang=en_us&edition=fundamental","pubTime":"2024-11-19 14:55","pubTimestamp":1731999357,"startTime":"0","endTime":"0","summary":"Neoleukin Therapeutics press release  : Q3  GAAP EPS of -$1.19 in-line.Cash, cash equivalents and investments as of September 30, 2024 were $139.0 million.The company continues to expect current cash, cash equivalents and marketable securities, together with an estimated $189.5 million in net proceeds from the private placement, to fund operations into the second half of 2027.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4305474-neoleukin-therapeutics-gaap-eps-of--119-in-line","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["NGNE"],"gpt_icon":0},{"id":"2484933561","title":"Neurogene Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2484933561","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484933561?lang=en_us&edition=fundamental","pubTime":"2024-11-19 07:08","pubTimestamp":1731971287,"startTime":"0","endTime":"0","summary":"Neurogene Inc reports results for the quarter ended September 30 - Earnings SummaryNeurogene Inc NGNE.OQ reported a quarterly adjusted loss of $1.19 per share for the quarter ended September 30, highe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL8N3MP1XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2484987040","title":"Neurogene Q3 2024 GAAP EPS $(1.19) Beats $(1.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987040","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987040?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:26","pubTimestamp":1731968785,"startTime":"0","endTime":"0","summary":"Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.22) by 2.46 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42050627/neurogene-q3-2024-gaap-eps-1-19-beats-1-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neurogene Q3 2024 GAAP EPS $(1.19) Beats $(1.22) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2484987053","title":"BRIEF-Neurogene Q3 Net Income USD -20.217 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987053","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987053?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968745,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Q3 Net Income USD -20.217 Million\n\n\nNov 18 (Reuters) - Neurogene Q3 operating expenses USD 22.18 million.\n\nQ3 operating income USD -22.18 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nPLX01796F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484987702","title":"Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987702?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA9CCKWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484870169","title":"Neurogene Inc  Q3 Shr View $-1.22 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2484870169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484870169?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA9CCKWY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484698705","title":"Neurogene Inc: Strong Cash Position Provides Runway Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2484698705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484698705?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA9CCKWY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484877729","title":"Neurogene Q3 Net Income USD -20.217 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2484877729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484877729?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nPLX01796F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484870999","title":"Press Release: Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2484870999","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484870999?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:25","pubTimestamp":1731968700,"startTime":"0","endTime":"0","summary":"Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett syndrome. Expects to provide an update on registrational trial design in first half of 2025. Strong cash position provides runway into the second half of 2027. Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2024 financial results and highlighted recent corporate updates.Third Quarter 2024 and Recent Highlights, and Anticipated Milestones. Phase 1/2 Trial of NGN-401 Gene Therapy for Treatment of Rett Syndrome. NGN-401 is currently being evaluated in an ongoing, open-label Phase 1/2 trial. Key updates include:. Announced today an update to the NGN-401 clinical trial. Following a treatment-related serious adverse event  in the. third participant dosed with 3E15 vg, Neurogene paused further use. of the 3E15 vg dose and does not plan to enroll any further. T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484165679","title":"Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2484165679","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484165679?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:48","pubTimestamp":1731941330,"startTime":"0","endTime":"0","summary":"Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett syndrome treatment.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2021/02/Stock-drugTest-09-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2021/02/Stock-drugTest-09-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/neurogene-stock-rett-rundrome-treatment-side-effect/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484675902","title":"Neurogene Shares Down 35.1% After Co to Stop Giving High Dose of Gene Therapy to Patients in Study as It Investigates Possible Side Effect","url":"https://stock-news.laohu8.com/highlight/detail?id=2484675902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484675902?lang=en_us&edition=fundamental","pubTime":"2024-11-18 22:32","pubTimestamp":1731940371,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP196:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484621004","title":"Neurogene Shares Down 20.5% Premarket After Co to Stop Giving High Dose of Gene Therapy to Patients in Study as It Investigates Possible Side Effect","url":"https://stock-news.laohu8.com/highlight/detail?id=2484621004","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484621004?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:47","pubTimestamp":1731934020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP0V0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484210076","title":"BUZZ-Neurogene drops after pausing part of gene therapy study due to serious side effect","url":"https://stock-news.laohu8.com/highlight/detail?id=2484210076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484210076?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:46","pubTimestamp":1731933990,"startTime":"0","endTime":"0","summary":"** Drug developer Neurogene's    shares fall 19% to $28 premarket   ** Company says it has paused testing high-dosage version of its experimental gene therapy after reporting a serious treatment related side-effect in one of the participants   ** Neurogene says the participant is in critical condition due to hyperinflammatory syndrome, a rare and life-threatening immune response   ** The gene therapy, NGN-401, is being developed to treat Rett syndrome, a rare genetic neurological disorder that occurs most often in girls and affects their ability to speak, walk, eat, and even breathe easily   ** Company says the U.S. Food and Drug Administration has allowed the early-mid-stage study to continue testing patients with the low-dosage version   ** As of last close, stock up 78% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2484621495","title":"Neurogene Receives FDA Approval to Proceed with Low-Dose Trial for Rett Syndrome Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2484621495","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484621495?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:39","pubTimestamp":1731933564,"startTime":"0","endTime":"0","summary":"Neurogene  said Monday that the US Food and Drug Administration has allowed the company to continue an early-stage trial using a lower dose of NGN-401, the company's intended gene therapy for Rett syndrome, a rare genetic neurological disorder.The company said it had paused the higher-dose cohort of the study following a previously disclosed emerging treatment-related serious adverse event in a trial participant. It also said it does not plan to enroll any more participants at the higher-dose level.So far, the company said it had not received reports of other treatment-related serious adverse events in the trial. However, it said that it no longer expects to complete enrollment of participants in the low-dose cohort in Q4.Shares of the company fell more than 18% in premarket activity.Price: 28.00, Change: -6.51, Percent Change: -18.88","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2484997621","title":"Neurogene Drops High-Dose Cohort of Gene-Therapy Study for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2484997621","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484997621?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:34","pubTimestamp":1731933240,"startTime":"0","endTime":"0","summary":"Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in grave condition.Neurogene on Monday said the U.S. Food and Drug Administration has completed a review of the safety data for NGN-401 and is allowing the New York company to proceed with the Phase 1/2 trial study using the low-dose cohort.Neurogene last week reported that it had become aware of an emerging treatment-related serious adverse event in a participant in the study's high-dose cohort, and the news sent its share price tumbling 44%.The company on Monday said the patient experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response that has been reported with systemic exposure to high doses of a benign virus used to deliver genetic material, and is in critical condition.Neurogene said it doesn't plan to enroll any further study participants","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurogene.com","stockEarnings":[{"period":"1week","weight":-0.4118},{"period":"1month","weight":-0.5819},{"period":"3month","weight":-0.419},{"period":"6month","weight":-0.3678},{"period":"1year","weight":0.4625},{"period":"ytd","weight":0.0475}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.087633},{"month":2,"riseRate":0.3,"avgChangeRate":-0.066901},{"month":3,"riseRate":0.5,"avgChangeRate":0.07464},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.109442},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.011201},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.067793},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.101505},{"month":8,"riseRate":0.909091,"avgChangeRate":0.860852},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.065613},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.066641},{"month":11,"riseRate":0.454545,"avgChangeRate":0.024404},{"month":12,"riseRate":0.7,"avgChangeRate":0.189368}],"exchange":"NASDAQ","name":"NEUROGENE INC","nameEN":"NEUROGENE INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUROGENE INC,NGNE,NEUROGENE INC股票,NEUROGENE INC股票老虎,NEUROGENE INC股票老虎国际,NEUROGENE INC行情,NEUROGENE INC股票行情,NEUROGENE INC股价,NEUROGENE INC股市,NEUROGENE INC股票价格,NEUROGENE INC股票交易,NEUROGENE INC股票购买,NEUROGENE INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction